BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

The put the Biosante cancer program into perspective. Dendreon while developing Provenge, the first FDA approved cancer vaccine went from a low of $2.61 to a high of $54.06 in approx. 13 months. the price has since pulled back significantly as initial revenue didn't meet expectations. But it has started climbing since Medicaire now covers the $93,000 treatment. Dendreon is no where near as diversified as Biosante. Biosante has arguably the largest cancer treatment portfolio in clinical trials, a number of which are ready for phase III clinical trials. They are just waiting for funding or a partner.
Once GVAX (cancer vaccine) is approved the fact that it it can be mass produced (it is not patient specific) will cut down on production cost allowing for a lower price while maintaining higher profits. Once GVAX is unleashed companies that use patient specific treatments have a real concern. Which treatment do you think the government or HMO's will be willing to subsidize.